[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576142":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":75,"collaborators":7,"id":77,"slug":7,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":7,"enrollmentInfo":86,"targetDuration":7,"studyType":89,"phases":7,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Pier Luigi Zinzani, MD","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+390512144042","pierluigi.zinzani@unibo.it",{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},"Cinzia Pellegrini, MD","+390512143680","cinzia.pellegrini@aosp.bo.it",[22,38,56],{"facility":23,"status":24,"city":25,"state":25,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"IRCCS Azienda Ospedaliero - Universitaria di Bologna","RECRUITING","Bologna","40138","Italy",{"type":29,"coordinates":30},"Point",[31,32],11.33875,44.49381,{"lat":32,"lon":31},[35,36,37],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"facility":39,"status":24,"city":40,"state":7,"zip":41,"country":27,"cosmosGeoPoint":42,"geoPoint":46,"contacts":47},"Azienda Ospedaliera Universitaria- POLICLINICO BARI","Bari","70124",{"type":29,"coordinates":43},[44,45],16.86982,41.12066,{"lat":45,"lon":44},[48,52,55],{"name":49,"role":14,"phone":50,"phoneExt":7,"email":51},"Pellegrino Musto, MD","+39 0805593471","pellegrino.musto@uniba.it",{"name":53,"role":14,"phone":7,"phoneExt":7,"email":54},"Francesco Gaudio, MD","francesco.gaudio@policlinico.ba.it",{"name":49,"role":11,"phone":7,"phoneExt":7,"email":7},{"facility":57,"status":24,"city":58,"state":7,"zip":59,"country":27,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Fondazione IRCCS Istituto Nazionale dei Tumori","Milan","20133",{"type":29,"coordinates":61},[62,63],12.59836,42.78235,{"lat":63,"lon":62},[66,70,74],{"name":67,"role":14,"phone":68,"phoneExt":7,"email":69},"Paolo Corradini, MD","+39 0223902950","paolo.corradini@unimi.it",{"name":71,"role":14,"phone":72,"phoneExt":7,"email":73},"Anna Guidetti, MD","+39 0223902175","anna.guidetti@istitutotumori.mi.it",{"name":67,"role":11,"phone":7,"phoneExt":7,"email":7},{"type":76,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100576142",false,"NCT06781450","Study in Patients With Relapsed\u002FRefractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context","Retrospective Observational Study in Patients With Relapsed \u002F Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context","PRIMICI","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of Primary Mediastinal B Cell Lymphoma Relapsed\u002FRefractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a real-life context with till Novembre 2021\n2. Age ≥ 18 years at enrollment\n3. Signature of written informed consent (where applicable)\n\nExclusion Criteria:\n\n1\\. Primary Mediastinal B Cell Lymphoma Relapsed\u002FRefractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a clinical trial context.","ALL","18 Years",{"count":87,"type":88},50,"ESTIMATED","OBSERVATIONAL","Observational, Non-Interventional, Retrospective, Multicenter Study Focusing on the Efficacy and Safety of Pembrolizumab Monotherapy and Nivolumab in Combination With Brentuximab Vedotin in Clinical Practice Patients With Primary Mediastinal B Cell Lymphoma Relapsed\u002FRefractory",[92],"Primary Mediastinal B Cell Lymphoma",[94,95,96],"pembrolizumab","nivolumab","brentuximab vedotin","2025-01-28",{"date":99,"type":100},"2025-01-30","ACTUAL",{"date":102,"type":100},"2022-04-23",{"date":104,"type":88},"2025-12",{"name":5,"class":6},3]